TG THERAPEUTICS INC. - COMMON STOCK

TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

18 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

18 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

15 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

08 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

01 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results

28 Feb 2024 07:00:01 By Nasdaq GlobeNewswire

TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)

27 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)

26 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update

23 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

20 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

10 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases

09 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

05 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference

27 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference

03 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

01 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update

30 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

12 Oct 2023 11:00:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

11 Oct 2023 10:30:26 By Nasdaq GlobeNewswire

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

02 Oct 2023 07:30:00 By Nasdaq GlobeNewswire